CFMS Key Statistics, Chart & Performance
The current stock price of CFMS is 2.26 USD. In the past month the price increased by 0.89%. In the past year, price decreased by -65.23%.
CFMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About CFMS
Company Profile
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 295 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The firm offers knee replacement products and knee replacement products. The firm's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The firm owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
Company Info
Conformis Inc
600 Technology Drive
Billerica MASSACHUSETTS 01821 US
CEO: Mark A. Augusti
Employees: 295
Phone: 17813459001.0
Conformis Inc / CFMS FAQ
Can you describe the business of Conformis Inc?
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 295 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The firm offers knee replacement products and knee replacement products. The firm's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The firm owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
What is the stock price of Conformis Inc today?
The current stock price of CFMS is 2.26 USD.
What is the dividend status of Conformis Inc?
CFMS does not pay a dividend.
What is the ChartMill rating of Conformis Inc stock?
CFMS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is Conformis Inc (CFMS) stock traded?
CFMS stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of Conformis Inc (CFMS)?
Conformis Inc (CFMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.61).
CFMS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CFMS. When comparing the yearly performance of all stocks, CFMS is one of the better performing stocks in the market, outperforming 89.18% of all stocks.
CFMS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CFMS. CFMS may be in some trouble as it scores bad on both profitability and health.
CFMS Financial Highlights
Over the last trailing twelve months CFMS reported a non-GAAP Earnings per Share(EPS) of -5.61. The EPS increased by 34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.64 |
CFMS Forecast & Estimates
8 analysts have analysed CFMS and the average price target is 2.32 USD. This implies a price increase of 2.45% is expected in the next year compared to the current price of 2.26.
For the next year, analysts expect an EPS growth of 24.27% and a revenue growth -8.57% for CFMS